Mineralys Therapeutics, Inc.
MLYS
$14.89
$0.2751.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 54.92% | 58.57% | 66.63% | 65.73% | 82.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.96% | 91.75% | 127.27% | 151.44% | 179.63% |
| Operating Income | -50.96% | -91.75% | -127.27% | -151.44% | -179.63% |
| Income Before Tax | -59.41% | -107.62% | -147.31% | -170.85% | -195.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.41% | -107.62% | -147.31% | -170.85% | -195.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.41% | -107.62% | -147.31% | -170.85% | -195.48% |
| EBIT | -50.96% | -91.75% | -127.27% | -151.44% | -179.63% |
| EBITDA | -152.14% | -469.77% | -- | -- | -- |
| EPS Basic | -31.53% | -70.94% | -82.83% | -4.68% | 29.49% |
| Normalized Basic EPS | -31.53% | -70.93% | -82.83% | -4.68% | 29.49% |
| EPS Diluted | -31.53% | -70.94% | -82.83% | -4.68% | 29.49% |
| Normalized Diluted EPS | -31.53% | -70.93% | -82.83% | -4.68% | 29.49% |
| Average Basic Shares Outstanding | 25.31% | 22.84% | 34.24% | 67.94% | 132.65% |
| Average Diluted Shares Outstanding | 25.31% | 22.84% | 34.24% | 67.94% | 132.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |